Just one punters view.... but two immediate thoughts.
1. To have this stable clinical response in the vast majority of these early patients is an extremely good start.
2. And to have got to this position in the 15 months since the IPO of this company back in August of last year.... is nothing short of brilliant.
It’s a telling testament to both the CEO Prof Kelly.... and the very able team he has recruited along the way. I am mightily impressed.... now let’s see what the market makes of the news.
Apples
Ann: Promising Interim Clinical Data for NOX66, page-3
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
